NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

NGM282, an engineered fibroblast growth factor 19 analogue, rapidly and significantly reduced liver fat content in a multicenter, randomized, double‐blind, placebo‐controlled study in patients with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). However, it is unclear whether these changes wou...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephen A., Rossi, Stephen J., Paredes, Angelo H., Trotter, James F., Bashir, Mustafa R., Guy, Cynthia D., Banerjee, Rajarshi, Jaros, Mark J., Owers, Sandra, Baxter, Bryan A., Ling, Lei, DePaoli, Alex M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187438/
https://www.ncbi.nlm.nih.gov/pubmed/30805949
http://dx.doi.org/10.1002/hep.30590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187438/
https://www.ncbi.nlm.nih.gov/pubmed/30805949
http://dx.doi.org/10.1002/hep.30590

Ejemplares similares